NCT01058785 - Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions

Lung NeoplasmCarcinoma, Bronchogenic

Interventions

BIOLOGICAL

Lucanix

Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.

Trial Locations (3)

70006

Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD, and Janet Burroff MD APM, Metairie

75201

Mary Crowley Medical Research Center, Dallas

92658

Hoag Cancer Center, Newport Beach